pioglitazone has been researched along with Osteoporosis in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 9.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| "The aim of this study was to investigate the effects of pioglitazone or metformin on bone mass and atherosclerosis in patients with type 2 diabetes." | 5.14 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. ( Kanazawa, I; Kurioka, S; Sugimoto, T; Yamaguchi, T; Yamamoto, M; Yamauchi, M; Yano, S, 2010) |
| "Pioglitazone treatment significantly increased urinary calcium, serum TRAP, mRNA expression of RANKL, PPAR-γ as well as significantly decreased Runx2, OPG, osteocalcin and AMPK levels in diabetic rats." | 1.46 | Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. ( Adil, M; Kandhare, AD; Mansoori, MN; Sharma, M; Singh, D, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tominaga, A | 1 |
| Wada, K | 1 |
| Okazaki, K | 1 |
| Nishi, H | 1 |
| Terayama, Y | 1 |
| Kato, Y | 1 |
| Jacob, JJ | 1 |
| Paul, TV | 1 |
| Adil, M | 1 |
| Mansoori, MN | 1 |
| Singh, D | 1 |
| Kandhare, AD | 1 |
| Sharma, M | 1 |
| Debiais, F | 1 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Yano, S | 1 |
| Yamamoto, M | 1 |
| Yamauchi, M | 1 |
| Kurioka, S | 1 |
| Sugimoto, T | 1 |
| Lecka-Czernik, B | 1 |
| Kurra, S | 1 |
| Siris, E | 1 |
| Beck, GR | 1 |
| Khazai, NB | 1 |
| Bouloux, GF | 1 |
| Camalier, CE | 1 |
| Lin, Y | 1 |
| Garneys, LM | 1 |
| Siqueira, J | 1 |
| Peng, L | 1 |
| Pasquel, F | 1 |
| Umpierrez, D | 1 |
| Smiley, D | 1 |
| Umpierrez, GE | 1 |
| Meymeh, RH | 1 |
| Wooltorton, E | 1 |
| Quesada-Gómez, JM | 1 |
| Serrano-Alferez, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study[NCT00927355] | 10 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00927355)
Timeframe: 6 months
| Intervention | percent change from baseline to 6 months (Mean) |
|---|---|
| Pioglitazone-Femoral Neck BMD | -4 |
| Placebo-Femoral Neck BMD | -2.6 |
| Pioglitazone -Lumbar Spine BMD | -1.1 |
| Placebo - Lumbar Spine BMD | 1.9 |
To determine the effect of PIO (pioglitazone) on BMSC (bone marrow stem cell) lineage choice in vivo, a bone marrow aspiration was obtained from patients at baseline and after 6 months of treatment with PIO or placebo. The bone marrow was used for ex vivo CFU-OB (Colony forming units-Osteoblast) and CFU-AD assays using the same protocol described for the in vitro studies previously. We also analyzed the number of total colonies per patient at both baseline and final visit. (NCT00927355)
Timeframe: 6 months
| Intervention | percent change from baseline to 6months (Mean) |
|---|---|
| Pioglitazone-Osteoblast CFU (Colony Forming Units) | 0 |
| Placebo-OSteoblast CFU | 12 |
| Pioglitazone-Adipocyte CFU | 4 |
| Placebo-Adipocyte CFU | -7 |
(NCT00927355)
Timeframe: 6 months
| Intervention | percent change from baseline (Mean) |
|---|---|
| Pioglitazone-Adiponectin | 78.7 |
| Placebo-Adiponectin | -0.6 |
| Pioglitazone-CTX | -9.2 |
| Placebo-CTX | 0.2 |
| Pioglitazone-OSc | 3.6 |
| Placebo - Osc | -5 |
1 review available for pioglitazone and Osteoporosis
| Article | Year |
|---|---|
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Topics: Animals; Bone Density; Cell Differentiation; Diabetes Mellitus, Type 2; Drug Combinations; Drug Ther | 2010 |
2 trials available for pioglitazone and Osteoporosis
| Article | Year |
|---|---|
Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Topics: Aged; Atherosclerosis; Biomarkers; Blood Glucose; Body Weight; Bone Density; Collagen; Diabetes Mell | 2010 |
The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
Topics: Adipocytes; Adipogenesis; Bone Density; Cell Differentiation; Colony-Forming Units Assay; Diabetes M | 2013 |
7 other studies available for pioglitazone and Osteoporosis
| Article | Year |
|---|---|
Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?."
Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Humans; Osteoporosis; Pioglitazone | 2022 |
Romosozumab and cardiovascular safety-should we learn lessons from pioglitazone?
Topics: Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Humans; Osteoporosis; Piogli | 2022 |
Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk.
Topics: Animals; Berberine; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Expe | 2017 |
Thiazolidinediones: antidiabetic agents with effects on bone.
Topics: Aged; Animals; Bone and Bones; Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Disease Mod | 2009 |
Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures.
Topics: Accidental Falls; Bone and Bones; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellit | 2011 |
Diabetes drug pioglitazone (Actos): risk of fracture.
Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Osteoporosis; | 2007 |
Nonhypoglycemic effects of thiazolidinediones.
Topics: Adipocytes; Humans; Hypoglycemic Agents; Osteogenesis; Osteoporosis; Pioglitazone; Rosiglitazone; Th | 2001 |